AstraZeneca’s EsoBiotec acquisition is the latest in a series of deals struck by the pharma giant to secure a place in the next wave of cell therapies for cancer and immune-mediated diseases. EsoBiotec’s allogeneic cell therapies are made by the in vivo reprogramming of a patient’s immune cells.
The post AstraZeneca Aims to Make Cell Therapy More Accessible With $425M EsoBiotec Acquisition appeared first on MedCity News.
